In Bio-Rad Labs., Inc. v. 10X
Genomics Inc., No. 2019-2255 (Fed. Cir. Aug. 3, 2020), the
Federal Circuit rejected 10X's prosecution history estoppel and
claim vitiation defenses and upheld the jury's finding of
willful infringement under the doctrine of equivalents.
Bio-Rad sued 10X for infringement of three patents covering
microscopic droplets of fluids for biochemical reactions, often
called "labs-on-a-chip." Bio-Rad amended the patents'
claim language during prosecution to claim "a non-fluorinated
microchannel," and further argued that, unlike the prior art,
the claims require the microchannel be "chemically similar to
the carrier fluid and chemically different from the channel
walls." 10X argued that its product, which includes 0.02% of a
fluorine-containing resin in its microchannels, did not
infringe.